Small Business Innovation Research (SBIR) Program Contract Solicitation (PHS 2012-1) Now Available
Release
Date: August 25, 2011
Contract
Proposal Receipt Date: November 7, 2011
National Institutes of Health (NIH)
Centers for Disease Control and Prevention (CDC)
Innovative technologies and methodologies fuel progress in biomedical and behavioral research and represent an increasingly important area of the economy. The Small Business Innovation Research (SBIR) program provides support for research and development (R&D) of new or improved technologies and methodologies that have the potential to succeed as commercial products.
The purpose of this notice is to (1) announce the issuance of the Solicitation of the National Institutes of Health and the Centers for Disease Control and Prevention for Small Business Innovation Research Contract Proposals (PHS 2012-1) with a receipt date of November 7, 2011; and (2) inform the public about the opportunities that the SBIR program offers to small business concerns as well as to scientists at research institutions.
The SBIR legislation requires the Public Health Service (PHS), Department of Health and Human Services, and certain other Federal agencies to reserve 2.5 percent of their extramural research or R&D budgets for an SBIR program. (The NIH SBIR set-aside requirement for FY 2011 is $609 million.)
The offeror organization must be a small business concern as defined by the Small Business Administration and described in the Contract Solicitation. The primary employment of the principal investigator MUST be with the small business concern at the time of award and during the conduct of the proposed project. In accord with the intent of the SBIR program to increase private sector commercialization of innovations derived from Federal R&D, scientists at research institutions can play an important role in an SBIR project by serving as consultants and/or subcontractors to the small business concern. Generally, up to 1/3 of the Phase I budget may be spent on consultant and/or subcontractual costs, and, generally, up to 1/2 of the Phase II budget may be spent on such costs. In this manner, a small business concern with limited expertise and/or research facilities may benefit from teaming with a scientist(s) at a research institution; for the scientist(s) at a research institution, this team effort provides support for R&D not otherwise obtained. The SBIR program consists of the following three phases:
PHASE I: The objective of this phase is to determine the scientific and technical merit and feasibility and potential for commercialization of the proposed research or R&D efforts and the quality of performance of the small business concern, before consideration of further Federal support in Phase II. Generally, Phase I SBIR awards do not exceed $150,000 for direct costs, Facilities and Administrative (F&A) costs, and negotiated fixed fee for a period generally not to exceed six months.
PHASE II: The objective of this phase is to continue the research or R&D efforts initiated in Phase I. Funding shall be based on the results of Phase I and the scientific and technical merit and commercial potential of the Phase II proposal. Only Phase I contractors are eligible to apply for Phase II funding, and Phase II proposals may be submitted ONLY upon the request of the Contracting Officer. (However, see "Fast-Track" Initiative below.) Generally, Phase II awards do not exceed $1,000,000 for direct costs, F&A costs, and negotiated fixed fee for a period generally not to exceed two years. Only one Phase II award may be made for any SBIR project.
PHASE III: The objective of this phase is for the small business concern to pursue, with non-SBIR funds, the commercialization of the results of the research or R&D funded in Phases I and II.
"FAST-TRACK" INITIATIVE: (Applicable only to proposals submitted to the NIH and only if an awarding component indicates that it is accepting Fast-Track proposals for a particular topic.)
The Fast-Track initiative is an opportunity for small business concerns to submit both a Phase I and Phase II proposal for concurrent peer review. This initiative also has the potential to minimize any funding gap between Phase I and Phase II. Proposals must be prepared in accordance with Phase I and Phase II proposal preparation instructions.
Following are the research topics contained in the PHS 2012-1 Solicitation:
National Institutes of Health (NIH)
National Cancer Institute (NCI)
255 Development of Anticancer Agents
277 Development of Companion Diagnostics
291 Development of Radiation Modulators For Use During Radiotherapy
300 Reformulation of Cancer Therapeutics using Nanotechnology
301 Probing Tumor Microenvironment Using In Vivo Nanotechnology-based Sensors
306 Development of Innovative Algorithms for Processing & Analysis of In Vivo Images
307 Novel Imaging Agents to Expand the Clinical Toolkit for Cancer Diagnosis, Staging, and Treatment
308 Automated Collection, Storage, Analysis, and Reporting Systems for Dietary Images
309 Development of Low Cost, Small Sample Multi-Analyte Technologies for Cancer Diagnosis, Prognosis and Early Detection
310 Simplified Tissue Microarray Instrument For Clinical and Research Settings (NIH Technology Transfer)
311 High Throughput Isolation of Antigen Specific T-cells for Cancer Therapy (NIH Technology Transfer)
312 Generation and Qualification of Site-specific Post-translationally Modified Proteins for Use as Calibrators in Pharmacodynamic (PD) Assays
National Center for Research Resources (NCRR)
015 Development of an Integrated Automated High Throughput Platform for Large-Scale Genetic and Therapeutic Screening in Zebrafish
National Heart, Lung and Blood Institute (NHLBI)
044 Development of Induced Pluripotent Stem (iPS) Cell Lines for Use in Cell-based Bioassays
058 Novel Technologies for Powering Ventricular Assist Devices
063 Reagents for Studying Human Lung Cell Biology and Cellular Function
064 Novel Technologies for Assessing Lipoprotein Sub-fractions
065 Computer Generated Diet and Exercise Reminders Promoting Cardiovascular Health
066 Haptoglobin Treatment to Reduce Complications of Sickle Cell Disease
067 Transmit-receive Surface Array Coils for MRI of Patients with Internal Conductive Devices
068 Multilayer-coated Gratings for Phase-Contrast Computed Tomography
069 Wireless Physiologic Telemetry for Interventional MRI
070 Bioabsorbable Stents for Pediatric Pulmonary Artery Stenosis and Aortic Coarctation
071 Electrophysiologic Catheters for Interventional MRI Ablation of Ventricular Tachycardia
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
044 Development of Novel Compounds to Treat Alcohol Use Disorders
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
075 A Low Molecular Weight Thyroid-Stimulating Hormone Receptor Agonist for Thyroid Cancer (NIH Technology Transfer)
National Institute on Drug Abuse (NIDA)
139 Confirming Compliance with Experimental Pharmacotherapy Treatment of Drug Abuse
140 Development of a Solid Oral Dosage Form for Fenobam
141 Recovery Warrior: Behavioral Activation Video Game for Substance Abuse via a Commercially Available Active & Interactive Gaming Platform (e.g, Wii, Play Station Move, or Xbox Kinect)
142 Highly Effective Methods for Systemic In Vivo Targeted Delivery of shRNAi to the Brain for Treatment of Substance Use Disorders and Other Brain Disorders
143 Feasibility of Development of RNAi-based Therapeutics for Treatment of HIV and HCV Infections in Drug Abusing Populations
144 Smokescreen: Genetic Screening Tool for Tobacco Dependence and Treatment Approaches
145 Feedback-regulated Naloxone Delivery Device to Prevent Opiate Overdose Deaths
146 Drugged Driving: Future Research Directions
Centers for Disease Control and Prevention (CDC)
Center for Global Health
001 The Development of Lateral Flow Immunochromatographic Devices to Detect Antibodies
002 Development of a Blood Donor Screening Test to Prevent Transfusion Transmitted Babesiosis
National Center on Birth Defects and Developmental Disabilities (NCBDDD)
015 Development of an Assay to Rapidly Determine Folate Insufficiency in the Field
National Center for Emerging Zoonotic and Infectious Diseases (NCEZID)
001 Vaccine Adverse Event Reporting System (VAERS) Application for Smartphone
002 Development of Rapid, Point-of-Care Tests for Diagnosis of Fungal Infections
National Center for HIV/AIDs, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)
031 Testing the Efficacy of HIV Prevention Strategies in Nonhuman Primate Models
032 Data Mining Software for Large-Scale Analyses of Infections Caused by Hepatitis Viruses
033 Developing a Location-Based Application to Identify Adolescent-Friendly Health Care Services
Office of Public Health Preparedness and Response (OPHPR)
001 Emergency Vehicle Proximity Alert System
Eligibility requirements, definitions, submission
procedures, review considerations, contract proposal forms and instructions,
and other pertinent information, including the "Fast-Track"
Initiative, are contained in the Solicitation (PHS 2012-1). The Solicitation,
including contract proposal forms, is available electronically through the NIH
"Small Business
Research Funding Opportunities Web site. See SBIR Phase I Contract
Solicitation PHS 2012-1 (PDF [https://grants.nih.gov/grants/funding/SBIRContract/PHS2012-1.pdf]
or MS Word [https://grants.nih.gov/grants/funding/SBIRContract/PHS2012-1.doc]).
Be sure to use the appropriate CONTRACT PROPOSAL forms as they differ from the
SF424 (R&R) GRANT application forms.
Note: The SBIR Phase I Contract Solicitation is available ONLY via electronic
means. Potential offerors are encouraged to check the NIH Small Business
Research Funding Opportunities Web site for updates on the program. Any
updates or corrections to the Solicitation will be posted there.
Contracting Officers
Any small business concern that intends to submit an SBIR contract proposal
under this Solicitation should provide the appropriate contracting officer(s)
with early, written notice of its intent, giving its name, address, e-mail,
telephone, and topic number(s). If a topic is modified or canceled before the
Solicitation closes, only those companies that have expressed such intent will
be notified.
National Institutes of
Health (NIH)
Ms. Anita Hughes
Phone: (301) 435-3805
Fax: (301) 480-0309
Email: [email protected]
Mr. John Taylor
Phone: (301) 435-0327
Fax: (301) 480-3430
E-mail: [email protected]
Mr. John Taylor
Phone: (301) 435-0327
Fax: (301) 480-3338
E-mail: [email protected]
Mr. Matthew Packard
Phone: (301) 443-3041
Fax: (301) 443-3891
Email: [email protected]
Ms. Anita Hughes
Phone: (301) 435-3805
Fax: (301) 480-0309
E-mail: [email protected]
Mr. Brian O Laughlin
Phone: (301) 443-6677
Fax: (301) 443-7595
Email: [email protected]
Centers for Disease Control and Prevention (CDC)
For general administrative SBIR program questions, contact:
Dr. Paul Smutz
Office of Extramural Research
Office of the Associate Director for Science
Phone: (404) 639-4783
Fax (404) 639-4903
Email: [email protected]
Carlos Smiley
Contracting Officer
Phone: (770) 488-1517
Fax: (770) 488-2688
E-mail: [email protected]
Theresa Routh-Murphy
Contracting Officer
Phone: (770) 488-2713
Fax: (770) 488-2778
Email: [email protected]
Charlene Allison
Contracting Officer
Phone: (770) 488.2841
Fax: (770).488.4088
E-mail: [email protected]
Julio Lopez
Contracting Officer
Phone: (770) 488-2892
Fax: (770) 488-2868
E-mail: [email protected]
Vivian Hubbs
Contracting Officer, Lead
Phone: (770) 488-2647
Fax: (770) 488-2670
E-mail: [email protected]
Those interested in the PHS small business research GRANT programs, where
investigator-initiated research ideas are encouraged, are invited to access the Omnibus Solicitation
of the Public Health Service for Small Business Innovation Research (SBIR) and
Small Business Technology Transfer (STTR) Grant Applications (PHS 2011-2).
There is one grant application due date (December 5, 2011) remaining for
calendar year 2011.
To understand better the differences between grants and contracts, see Contracts
vs. Grants: What's the difference?
and Human Services (HHS)
